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Background: Management of low back pain after spinal surgeries is one of the most 
challenging problems in pain medicine. Transforaminal lumbar epidural steroid injection has 
been used with inconsistent response. Most patients require multiple and frequent injections 
due to high recurrence of back pain. 
Objective: To find out whether the addition of hyaluronidase to the epidural injectate affects 
the quality and duration of analgesia in patients with low back pain secondary to failed back 
surgery syndrome. 
Study Design: Prospective randomized trial.
Methods: The study was registered in the Government Clinical Trial registry and the protocol 
was reviewed and approved by the institutional review board. After obtaining an informed 
consent, 25 patients with low back pain due to failed back syndrome were randomly assigned 
to receive a transforaminal epidural injection of hyaluronidase 1500 IU (HYL) or normal saline 
(NSL) to a mixture of bupivacaine 0.5% (1 mL) and triamcinolone 40mg (1 mL) in a double-
blind fashion. An interventional pain specialist using fluoroscopic guidance performed all 
epidural injections. The patients received a comprehensive neurological examination by a 
non-interventional pain specialist who was blinded to the treatment during their follow-up 
visits, scheduled one, 2, and 4 weeks after the intervention. Numerical pain scores, analgesic 
requirement, and satisfaction scores were recorded during every visit.
Results: There was no difference in demographic data between the 2 groups. Pain scores and 
total analgesic requirement were significantly lower in the HYL group at 2 and 4 weeks after 
blockade (P < 0.01). Patient satisfaction was higher in the HYL group.
Limitations: The study was limited by a relatively small sample size. 
Conclusion: We conclude that adding hyaluronidase to the epidural injectate was effective 
in the management of chronic low back pain in patients with failed back surgery syndrome 
demonstrated over a period of 4 weeks.
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Chronic low back pain is the second most common cause for seeing a physician in the United States and it alone is responsible for total or 
partial disability of at least 7 million Americans (1,2). 
The lifetime prevalence of low back pain is estimated 
between 40% and 60% (3). The estimated direct and 
indirect cost of treatment for back pain exceeds $50 
billion in addition to 93 million lost workdays per year 
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objective of this study was to compare the quality of 
pain relief and functional state in response to the addi-
tion of hyaluronidase in patients with FBSS who were 
treated with transforaminal lumbar epidural injection 
of steroids. We hypothesized that the patient who 
received hyaluronidase would have less pain, require 
lesser amount of analgesics, and have a more active 
lifestyle compared to those who did not.
Methods
The experimental design and protocol of the clini-
cal trial were reviewed and approved by the Medical Re-
search Ethics Committee at Tehran University of Medical 
Sciences. Additionally, the study was registered in the 
Iranian registry for clinical trials (IRCT201108137313N1). 
The study design was a double-blinded randomized 
control trial. 
Inclusion and Exclusion Criteria
 FBSS is defined as persistent (at least 6 month) pain 
and or disability following laminectomy with or with-
out sensory-motor neurological deficits or any form of 
urinary or bowel incontinence. Patients between the 
ages of 20 to 75 years old suffering from persistent (> 
6 months) back pain following laminectomy for spinal 
canal stenosis and/or discectomy for herniated nucleus 
pulposus documented by magnetic resonance imag-
ing (MRI) were included for screening and enrollment. 
Patients were excluded if they suffered from sacroiliac 
joint disease, facet joint arthritis, severe cardiopulmo-
nary disease, uncontrolled diabetes, morbid obesity, 
addiction, infection, and coagulation disorders that 
prohibited lumber epidural injections. None of the pa-
tients was on opioid medications for pain management 
before or during the study period.
Experimental Design
A total of 33 patients with FBSS who were referred 
to the Tehran University outpatient pain clinic were 
screened, and 25 patients who were scheduled for elec-
tive transforaminal lumber epidural steroid injection 
(TFESI) were enrolled in the study. After obtaining an 
informed consent, using robust (pseudo-) random num-
ber generation software, the patients were randomly 
assigned to receive one of the following formulations 
in the epidural spaces:
1. Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 
mL) + Saline solution 10% (2 mL) + Hyaluronidase 
1,500 IU reconstituted in 1 mL distilled water (HYL)
(4). Annually, between 300,000 and 400,000 surgeries 
are performed for chronic low back pain; however, the 
success rate for this treatment modality is only 50% to 
60% (5). Despite advances in surgical technology, the 
rates of failure for back surgery have not declined over 
past 2 decades. Failed back surgery syndrome (FBSS) is a 
chronic pain condition that has considerable impact on 
the patient and health care system (6). This condition 
may cause many social, occupational, and individual 
problems, so finding an effective, rapid, and less 
complicated method for pain control and treatment 
has been always desired.
Lumbar epidural injection of long-acting steroids is 
commonly used by interventional pain specialists to al-
leviate low back pain. The duration of analgesia varies 
among patients with FBSS and ranges from 15 days up to 
180 days. Although there is not a consensus on the effect 
of steroids in reducing pain after epidural injection, the 
anti-inflammatory effects are the probable mechanism 
where the levels of tissue phospholipase and prostaglan-
dins are decreased by steroids. In addition to anatomical 
impingement of the nerve roots by herniation and degen-
eration of the intervertebral discs, spinal canal stenosis, 
and spondylolisthesis, damage caused by inflammation of 
the surrounding tissues and swelling of the nerve roots 
may result in radiculopathy and related pain symptoms. 
Glucocorticoids are the most common medications ad-
ministered epidurally for chronic low back pain due to 
their prolonged pain relieving effects (7). 
Following surgical manipulation of the spine and 
surrounding tissues, significant changes occur in the 
epidural space that may attenuate pharmacological 
response to epidural steroids. Fibrosis and adhesion of 
the soft tissue generate multiple septations and elimi-
nate the normal continuity of the epidural space. This 
continuity is required for homogenous spread of the 
medications injected into the epidural space. Hypertonic 
saline (10%) with or without fibrinolytic enzymes such 
as hyaluronidase have been clinically used to lyse the 
adhesion during percutaneous epidural neuroplasty to 
decrease the local tissue edema and improve the pain 
(8). The effects of adding hyaluronidase during epi-
duroscopy and during transforaminal epidural steroid 
injection were independently examined by Geurts et al 
(7) and Devulder et al (9) which showed inconsistent 
results with the addition of hyaluronidase. 
In addition to the effectiveness of hyaluronidase, 
there is much controversy about the concentration and 
total dose of the enzyme with transforaminal epidural 
injection especially in patients with FBSS. The main 
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2.  Bupivacaine 5 mg (1 mL) + Triamcinolone 40 mg (1 
mL) + Saline solution 10% (2 mL) + 1 mL distilled 
water (NSL)
Study drugs were compounded and prepared by a 
research pharmacist and the interventional pain physi-
cian who performed the procedure was blinded to the 
composition of the drug that was injected.
Patient Preparation and Technical Description
 The level and cause of neural compression and 
radiculopathy after surgery (disc herniation or spinal 
canal stenosis) were recorded. After transferring patients 
to the interventional pain procedure room, mild sedation 
was achieved using intravenous administration of mid-
azolam 2 mg and fentanyl 100 mcg. Patients were placed 
in a prone position and the back was prepped with 
chlorohexidine 3% and local anesthesia was achieved 
by epidermal and subcutaneous administration of 3 mL 
Lidocaine 1% injectate. Under fluoroscopic guidance, a 
blunt Coude 22G (Epimed) needle was passed through an 
introducer and was advanced into the epidural space via 
a transforaminal approach. The position of the needle 
was confirmed by injecting 3 – 5 mL of contrast media Vi-
sipaqueTM (iodixanol) and examining its epidural spread 
on antero-posterior and lateral views of fluoroscopy. The 
interventional pain specialist, who was blinded to the 
nature of the injectate, then injected the study drug into 
the epidural space. The patients were then transferred 
to the Peri-Anesthesia Care Unit (PACU) for monitoring 
vital signs, pain levels, and possible neurological adverse 
events for 60 – 90 minutes. They were then discharged 
home in care of a responsible adult and advised not to 
drive for 24 hours. The pain intensity was evaluated by 
visual analogue scale (VAS) scores.
Assessment and Treatment of Post-epidural 
Pain
 VAS pain scores from 0 = no pain to 10 as maximum 
pain were used to assess the intensity of low back pain 
and the numerical rating was recorded both without 
moving (static) and on movement (dynamic). In patients 
with pain scores more than 3, celecoxib 100 mg oral 
capsule was prescribed. The above criteria and the total 
daily dose of celecoxib were assessed as follows: 1 = no 
need for drugs, 2 = less than 200 mg/day, 3 = equal to 
or more than 200 mg/day. More than 50% reduction 
in pain scores was considered as significant clinical re-
sponse to epidural injection.
Follow-up Visits and Pain Assessment
 Patients were advised to contact the treating 
pain physicians during administrative hours or the 
emergency medical care services in case of any adverse 
reaction or uncontrollable pain. All patients were 
reassessed for the location, intensity, and the nature 
of low back pain (whether the nature of back pain 
changed in comparison to the pre-procedure pain) 
one, 2, and 4 weeks after surgery. Focused neurologic 
examination (toe and heel walking; 2-point discrimi-
nation test; vibration test; sensation of touch, heat, 
and pressure; straight leg raising test (SLR); and deep 
tendon reflexes) (see Appendix I) was performed in 
addition to full documentation of static and dynamic 
pain using VAS scores during each follow-up visit and 
the results were recorded in a MS Excel-based data-
sheet. Patients were asked to answer a single ques-
tion satisfaction questionnaire regarding the quality 
of pain control (using Likert Scale) as follows: 1 = Ex-
tremely dissatisfied, 2 = Dissatisfied, 3 = Neutral, 4 = 
Satisfied, and 5 = Extremely satisfied. 
Data Management and Statistical Analyses
 All data variables were entered in an MS Excel 
database and exported to SPSS 11.5 version (Chicago, 
IL) for statistical analyses. Numerical rating of the 
static low back pain was the primary endpoint for the 
study. A 50% decrease in pain scores was considered 
a clinically significant response to epidural injection. 
At least 2 point difference in VAS score between the 
groups was considered clinically significant. Assum-
ing an alpha error of 0.05 and a beta error of 0.20, the 
power calculation was found to be 80% and there-
fore at least 10 patients in each group were required 
to detect statistical significance. Categorical data 
(the incidence of any adverse event) were analyzed 
using chi square test with Yate correction. Since pain 
and satisfaction scores did not follow a normal distri-
bution, a non-parametric Mann-Whitney U test was 
used to examine continuous variables and data were 
presented as median (interquartile range). ANOVA 
repeated measures were used to assess the progress 
or regression of pain scores at various time points. 
A multivariate regression model including the cause 
of radiculopathy, type of surgery, type of treatment, 
and age was constructed to identify the factors that 
may have contributed to a favorable outcome. The 
null hypotheses were rejected when P values were 
< 0.05.
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Results
Twenty-five patients ranging between 39 to 56 
years old with low back pain due to FBSS were enrolled 
in this study (12 patients were in the HYL and 13 patients 
in the NSL group). The demographic distribution of the 
patients was similar in both groups. Similarly, there was 
no difference in the etiology, character, motion depen-
dency, intensity, and duration of pain between the 2 
groups. In 23 out of 25 patients (92%), SLR at an angle 
of between 30 and 70 degrees elevation induced severe 
pain (Table 1).
All patients in both groups, regardless of the etiol-
ogy, demonstrated early complete pain relief (within 15 
minutes) following TFESI. In fact, the reported numeri-
cal pain scores were 0 in 92% of the patients. Early local 
anesthetic effect faded within 12 hours of TFESI as the 
anti-inflammatory mechanism became more of a player. 
Repeated measure analysis of the VAS pain scores over 
4 time points demonstrated significantly longer lasting 
analgesia in the HYL group than NSL group, P < 0.001 
(Table 2). Additionally, the total amount of ingested 
oral anti-inflammatory medication use was significantly 
less in the HYL group when compared to the NSL group, 
P < 0.001. This increase in celecoxib intake occurred 
10 days after epidural injection. More patients in the 
HYL group were satisfied with the level of pain control 
when compared to the NSL controls.
The nerve root originating between the fourth 
and fifth lumbar vertebrae was affected in 12 out 25 
patients (48%) which were followed by L3-L4 in 8 pa-
tients (32%) and L5-S1 in 6 patients (20%). There was 
no difference in the quality of pain relief and response 
to TFESI based on the involvement of any nerve roots. 
The cause of low back pain was due to a herniated disc 
in 15 patients while the remaining 10 patients suffered 
chronic low back pain because of spinal canal stenosis. 
The results of TFESI were more favorable in patients 
who presented with herniated disc rather than spinal 
stenosis, P < 0.01 (Fig. 1).
Univariate analyses were performed to identify 
the association of pre-injection conditions with a fa-
vorable response to TFESI. Hyaluronidase addition, the 
cause of FBSS, age of 50 or higher, and the subacute 
versus chronic duration of low back pain were selected 
to build a multivariate logistic regression. The results 
of this analysis are depicted in Table 3. In summary, 
Table 1. Demographic distribution and baseline pain 
characteristics.
HYL
(N = 12)
NSL
(N = 13)
P 
Value
Age (year) 45.9 ± 3.0 48.0 ± 2.3 0.30
Gender (Female/Male) 5/7 6/7 0.23
Body Weight (Kg) 69 ± 13 72 ± 12 0.15
Duration of Pain (month) 7.1 ± 3.0 8.0 ± 3.2 0.23
Herniated Discopathy 8 (67%) 7 (57%) 0.21
Spinal Stenosis 4 (33%) 6 (43%) 0.21
Motion-related component 4 (33%) 4 (31%) 0.12
Positive SLR* 11 (91.7%) 12 (92.3%) 0.20
Pre-ESI VAS Pain scores 3.1 ± 2.0 3.4 ± 1.5 0.10
* Pain induced by straight ipsilateral leg raising between 30 to 70 
degrees; ESI=Epidural Steroid Injection   
Table 2. Four-week follow-up responses to transforaminal epidural steroid injections and patient satisfaction.
Groups
Day-0
TFESI
Week-1
s/p TFESI
Week-2
s/p TFESI
Week-4
s/p TFESI
P 
Values
VAS Pain Scores
[Median (IQR)]
HYL 0 (0 – 0) 1 (0 – 2) 1 (0 – 3) 1.5 (1 – 4)
0.02
NSL 0 (0 – 1) 1 (0 – 2) 1.5 (1 – 3) 2.5 (2 – 5)
Number of Patients with > 50% decrease in NRS
HYL 12 11 11 10
0.01
NSL 13 10 7 6
Patients Satisfaction Score
HYL 4.9 ± 0.2 4.4 ± 0.3 4.2 ± 0.2 4.2 ± 0.2
0.001
NSL 4.4 ± 0.5 4 ± 0.5 3.5 ± 0.5 3.4 ± 0.1
Celecoxib Intake 
(mg/week)
HYL 700 ± 30 720 ± 70 750 ± 140 780 ± 140
0.01
NSL 720 ± 40 950 ± 180 1,350 ± 160 1,420 ± 250
Number of Patients on High Dose Celecoxib
HYL 0 1 1 1
0.04
NSL 0 1 2 3
Number of Patients with negative SLR
HYL 12 (100%) 10 (87.8%) 9 (80.1%) 9 (80.1%)
0.01
NSL 12 (93.3%) 8 (67%) 7 (53.8%) 6 (47.2%)
TFESI: Transforaminal Epidural Steroid Injection; SLR = Straight Leg Raising between 30 to 70 degrees; NRS: Numerical Rating of Pain Score
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the addition of hyaluronidase to the epidural steroid 
injection was the only independent factor which was 
associated with a favorable response, odds ratio = 
0.12 (0.08 – 0.87), P = 0.04. There was a trend among 
the patients with herniated disc to have a favorable 
response to TFESI, odds ratio = 0.65 (0.54 – 1.20), P = 
0.06 despite of the fact these patients had significantly 
better responses than those with spinal stenosis in uni-
variate analysis (Fig. 1). There was no difference with 
regards to the quality of pain control between patients 
50 years or older and those younger than 50 years 
old, and between the patients who presented with 
subacute symptoms compared to those who presented 
with more chronic symptoms. 
None of the patients in either group experienced 
any adverse event related to transforaminal injection 
of epidural steroid during one month follow-up period. 
They were specifically monitored for development of 
inadvertent subarachnoid injection, prolonged sensory-
motor block, long-term weakness of the limbs, epidural 
hematoma, infection, bladder dysfunction, and arach-
noiditis for 30 days following TFESI.
discussion 
Our study was an endeavor to analyze the effects 
of pharmacologic intervention alone using hyaluroni-
dase in alleviating the back pain specifically associated 
with FBSS and has shown promising results over a short 
period of time. We studied the effects of the addition 
of hyaluronidase to epidural steroid injections in the 
“difficult to treat” back pain population, measured by 
the quality of pain relief and improvement in function-
al state. We demonstrated that adding hyaluronidase 
to the injection compound increased the effectiveness 
of transforaminal epidural steroids in alleviating the 
intensity of the pain, prolonging the duration of an-
algesia, and decreasing the total dose of non-steroidal 
anti-inflammatory drugs used to treat chronic low back 
pain over a 4 week period after failed back surgery. 
The proteoglycan structure of cartilage tissue plays 
an important role in maintaining the consistency of 
intervertebral discs. The degenerative changes of the 
annulus fibrosus secondary to shearing forces results 
in protrusion of nucleus pulposus into the spinal canal 
with secondary impingement of the related nerve roots 
(10). These changes are associated local inflamma-
tory responses that enhance the stress over the nerve 
roots and exacerbation of the sciatica symptoms. Local 
release of inflammatory mediators within the disc and 
surrounding epidural space is further promoted by sur-
gical trauma such as laminectomy and development of 
posterior spinal instability (3,11).
The main explanation for this observation is the 
fact that following back surgery and periods of inflam-
matory processes involving the epidural space, fibro-
blastic activity increases as a part of repair mechanism 
(12). The chemical irritation and inflammatory reaction 
induced by leakage of the nucleus pulposus into the 
epidural space produces a significant degree of fibrosis 
and adhesion which contribute to low back pain and 
sciatica symptoms (13). Scar formation and local fibrosis 
of the dura matter following surgical manipulation of 
the epidural space during discectomy or laminectomy 
add to the underlying inflammatory process and exac-
erbate low back pain following back surgery (13). Low 
back pain caused by epidural fibrosis does not respond 
well to surgical decompression and some patients even 
report higher levels of pain following this intervention 
(8,14).
Table 3. Multivariate logistic regression analysis of  factors 
associated with a favorable response to TFESI.
Fig. 1. Kaplan Meier curve depicting the fraction of  the patients 
remaining pain-free over a follow-up period of  4 weeks. The most 
favorable results were seen among the patients who were treated 
for herniated disc (P < 0.001).
OR 95% 
Confidence 
Interval
P 
Value
HYL/NSL 0.12 0.08 – 0.87 0.04*
Herniated Disc vs. Spinal Stenosis 0.65 0.54 – 1.2 0.06
Age ≤ 50 yr vs. age > 50 yr old 1.23 0.75 – 3.78 0.65
Chronic vs. Subacute symptoms 2.12 0.89 – 6.67 0.52
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It is prudent that most of sciatica symptoms favor-
ably respond to anti-inflammatory treatment measures. 
Although the systemic administration of non-steroidal 
anti-inflammatory drugs (NSAID) along with physi-
cal therapy alleviates a large component of low back 
pain, a local injection of corticosteroids in the vicinity 
of inflamed nerve roots reduces regional swelling and 
decreases the mechanical stress caused by herniated 
disc(s). The role of corticosteroids in the reduction of 
inflammation and tissue edema is already well known. 
Pain control in FBSS remains a challenge and very 
few studies have been performed to show the efficacy 
of epidural steroids and hyaluronidase in the treatment 
of back pain. As described, adhesions and scar tissue 
play a major role in the evolution and pathophysiol-
ogy of pain in FBSS. Mechanical lysis of adhesions us-
ing percutaneous epiduroscopy has been studied and 
has shown promising results in patients with back pain 
associated with and without failed back syndrome or 
spinal stenosis (15-17). In the post lumbar surgery pa-
tients, Manchikanti et al (18) showed that percutane-
ous adhesiolysis was effective in 73% of patients over 
a 12 months period. On the other hand, Heavner et 
al (19) showed that percutaneous lysis of adhesions in 
itself improves the pain intensity with effects lasting as 
long as one year, but did not show any improvement 
in pain scores when hyaluronidase was added to the 
epidural solution (20). 
Hyaluronidase is a lysing enzyme, which suppos-
edly has the ability to disrupt the epidural scar tissue 
and adhesions thereby facilitating the spread and ef-
ficacy of injected corticosteroids. It also reduces fibrosis, 
which plays a major role in pain related to FBSS (20). 
There are very few trials that have studied the effects 
of hyaluronidase in the epidural space during epidur-
oscopy (7), nerve root sleeve injections (9), and caudal 
injections (21). In each of these studies the addition of 
hyaluronidase improved pain relief. The anti-inflamma-
tory effect of corticosteroids complements the effects 
of hyaluronidase in epidural neuroplasty (22). The re-
sults of the addition of hyaluronidase to the epidural 
space injectate in back pain have shown controversial 
results so far and mostly unproven. In addition, the ef-
fectiveness of hyaluronidase in producing pain relief in 
FBSS and spinal stenosis is largely unknown. 
In a study by Geurts et al (7), they reported that 
mechanical lysis of adhesions with epiduroscope and 
targeted injection of steroid and hyaluronidase showed 
significant reduction in chronic radicular pain. In anoth-
er study by Devulder et al (9), nerve root sleeve injection 
of corticosteroid, local anesthetic, and hyaluronidase 
failed to show a good outcome and pain relief with any 
of the solutions. Heavner et al (19) compared the use 
of epidural saline plus hyaluronidase to saline alone 
and did not show a significant difference in the clinical 
outcome. A recent prospective trial showed that the 
addition of hyaluronidase to caudal steroid and hyper-
tonic saline in patients with FBSS improves short-term 
pain control (21). The role of hypertonic saline is also of 
importance. Significant research and trials were done 
by Racz and colleagues showing the use of hypertonic 
saline in the epidural space for neurolytic purposes due 
to its osmotic action and anti-edema effects, hence re-
ducing local pressure on the nerve roots(23).
In our double-blinded, randomized control trial, 
we used a transforaminal approach to lumbar epidural 
steroid injections. This is a more specific approach to 
the nerve root lesions compared to interlaminar epidur-
al approach, especially in patients with radiculopathy 
associated with either herniated disc disease or spinal 
stenosis alone. Unlike the interlaminar method, the 
main volume of injected medication is spread in the 
anterior epidural space where the herniated discs 
are most affectrd (20). Therefore, the transforaminal 
approach is the preferred technique for injection of 
fibrolytic agents because of the needle’s proximity to 
the target site providing higher concentrations of the 
hyaluronidase in the scarred area (21-22).
Based on the review of the existing literature, the 
use of epidural hyaluronidase in back pain still remains 
controversial and mostly unproven. We studied the 
effects of the addition of hyaluronidase to epidural 
steroid injections in the “difficult to treat” back pain 
population, measured by the quality of pain relief and 
improvement in functional state. We classified our 
study population based on the etiology and included 
only a subset of FBSS patients who had either herni-
ated disc disease or spinal stenosis. In an attempt to 
reduce the confounding effects of other agents that 
may have an association with relief of pain, we tried 
to minimize the agents used to steroids and hyaluroni-
dase alone. We performed univariate and multivariate 
logistic regression to identify the association of other 
factors which could have led to a favorable response 
and found that addition of hyaluronidase is an inde-
pendent factor implicated in pain relief. Even though 
no significant association could be established between 
patients with herniated disc disease having a favorable 
response compared to spinal stenosis, there is a defini-
tive trend. One possible explanation for this difference 
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could be that radiculopathy secondary to herniated disc 
involves inflammation and chemical irritation of nerve 
roots from the contents of the disc in addition to me-
chanical compression which responds to corticosteroids 
better in comparison to spinal stenosis where mechani-
cal compression alone is involved.
One of the major limitations of the study was that, 
even though the patients had a better pain control 
and satisfaction level in the hyaluronidase group, the 
follow-up was limited to 4 weeks only, and therefore, 
whether there was a significant difference in pain 
relief over a long term is unknown. The number of 
patients enrolled was low. A higher number definitely 
would have increased the power of study and helped 
to extrapolate the results to the general population 
to a better degree, but per the statistical analysis, this 
number was sufficient to minimize the alpha and beta 
errors. 
conclusion
As pointed out, our study definitely strengthens 
the concept that addition of hyaluronidase has a posi-
tive impact on minimizing the pain scores, improving 
the quality of the analgesia and patient satisfaction, 
and decreasing analgesic requirements after epidural 
steroid injections, but in the future bigger randomized 
controlled trials are warranted to further verify this 
finding.
Appendix i
Definitions of the pain evaluation tests used
1.  Straight leg raising test: With the patient lying down on his or her back on an examination 
table or exam floor, the examiner lifted the patient’s leg while the knee was kept straight; if 
the patient experienced reproduction of back pain when the straight leg was at an angle of 
between 30 and 70 degrees, then the test was considered positive.
2.  Toe and heel walking test: Ability of the patients to walk on their toes and then on the heels 
was tested separately to check for the plantar flexion and dorsiflexion of the feet respectively. 
The results were recorded as positive or negative. 
3.  Two point discrimination tests:  The examiner alternated between touching the patient with 
one sharp point or with 2 sharp points on one of the toes and then repeated on the other 
toe. The patient was then asked to report back what s/he felt (one or 2 points). The smallest 
distance between 2 points at which the patient could still distinguish as 2 separate stimuli and 
not one, was recorded. The cut off used for normal discrimination was 30 mm.
4.  Deep Tendon Reflexes: Checked using a reflex hammer and graded as follows:
 0: absent reflex
 1+: trace, or seen only with reinforcement
 2+: normal
 3+: brisk
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